1. Home
  2. HYFM vs GANX Comparison

HYFM vs GANX Comparison

Compare HYFM & GANX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • HYFM
  • GANX
  • Stock Information
  • Founded
  • HYFM 1977
  • GANX 2017
  • Country
  • HYFM United States
  • GANX United States
  • Employees
  • HYFM N/A
  • GANX N/A
  • Industry
  • HYFM Industrial Machinery/Components
  • GANX Biotechnology: Pharmaceutical Preparations
  • Sector
  • HYFM Industrials
  • GANX Health Care
  • Exchange
  • HYFM Nasdaq
  • GANX Nasdaq
  • Market Cap
  • HYFM 38.1M
  • GANX 41.9M
  • IPO Year
  • HYFM 2020
  • GANX 2021
  • Fundamental
  • Price
  • HYFM $0.61
  • GANX $1.56
  • Analyst Decision
  • HYFM Hold
  • GANX Strong Buy
  • Analyst Count
  • HYFM 2
  • GANX 5
  • Target Price
  • HYFM $0.70
  • GANX $7.60
  • AVG Volume (30 Days)
  • HYFM 168.0K
  • GANX 214.8K
  • Earning Date
  • HYFM 11-07-2024
  • GANX 11-14-2024
  • Dividend Yield
  • HYFM N/A
  • GANX N/A
  • EPS Growth
  • HYFM N/A
  • GANX N/A
  • EPS
  • HYFM N/A
  • GANX N/A
  • Revenue
  • HYFM $200,158,000.00
  • GANX N/A
  • Revenue This Year
  • HYFM N/A
  • GANX N/A
  • Revenue Next Year
  • HYFM $3.93
  • GANX N/A
  • P/E Ratio
  • HYFM N/A
  • GANX N/A
  • Revenue Growth
  • HYFM N/A
  • GANX N/A
  • 52 Week Low
  • HYFM $0.43
  • GANX $0.89
  • 52 Week High
  • HYFM $1.20
  • GANX $5.33
  • Technical
  • Relative Strength Index (RSI)
  • HYFM 39.26
  • GANX 40.79
  • Support Level
  • HYFM $0.58
  • GANX $1.50
  • Resistance Level
  • HYFM $0.65
  • GANX $1.73
  • Average True Range (ATR)
  • HYFM 0.04
  • GANX 0.16
  • MACD
  • HYFM -0.02
  • GANX -0.00
  • Stochastic Oscillator
  • HYFM 11.06
  • GANX 16.22

About HYFM Hydrofarm Holdings Group Inc.

Hydrofarm Holdings Group Inc is a distributor and manufacturer of agriculture equipment and supplies. Some of its products includes lighting solutions, growing media (i.e., premium soils and soil alternatives), nutrients, equipment, and supplies sold under proprietary, exclusive/preferred brands, or non-exclusive/distributed brands. The business is organized into two operating segments, the U.S. and Canada.

About GANX Gain Therapeutics Inc.

Gain Therapeutics Inc is a biotechnology company developing novel small molecule therapeutics to treat diseases across, several therapeutics areas, including, lysosomal storage disorders, central nervous system disorders, metabolic disorders, and oncology. The company's clinical-stage product candidate, GT-02287, is being developed for the treatment of GBA1 Parkinson's disease. The company uses its computational target and drug discovery platform, Magellan, to discover novel allosteric binding sites on proteins implicated in disease and to identify proprietary small molecules that bind these sites to modulate protein function and treat the underlying cause of the disease. The company derives revenues from collaboration and licensing agreements.

Share on Social Networks: